Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

12.21
-0.3150-2.52%
Post-market: 12.210.00000.00%19:30 EDT
Volume:1.23M
Turnover:15.20M
Market Cap:1.26B
PE:-9.03
High:12.93
Open:12.72
Low:12.17
Close:12.52
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:0.71
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.31
PE(LYR):-8.28

Loading ...

Oric Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 06

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 06

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Jun 03

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 28

Oric Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
May 06

ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts

TIPRANKS
·
May 05

Piper Sandler Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
May 05

Guggenheim Remains a Buy on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
May 05

Oric Pharmaceuticals (ORIC) Receives a Buy from Wells Fargo

TIPRANKS
·
May 05

Oric Pharmaceuticals price target lowered to $16 from $17 at Citi

TIPRANKS
·
May 05

Oric Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate

Benzinga Earnings
·
May 05

Oric initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC

Reuters
·
May 05

Oric Q1 FY26 net loss widens to $35.77 million; R&D expenses rise to $31.44 million

Reuters
·
May 05

BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million

Reuters
·
May 05

Oric Pharmaceuticals Q1 Operating Expenses USD 39.619 Million

THOMSON REUTERS
·
May 05

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

GlobeNewswire
·
May 05

ORIC Pharma grants 216,000 stock options, 35,000 RSUs to new employees

Reuters
·
May 02

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 02